HIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo

Immunobiology

Volumn 219, Issue 7, 2014, Pages 547-553

  Jiang, Wen ^a   Zhang, Cai ^a   Tian, Zhigang ^a   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Gene transfer; Interleukin 15; Natural killer cell line; Natural killer cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN P30; PROTEIN P46; PROTEIN P80; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; FEMALE; IL 15 GENE; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL SURVIVAL; COCULTURE; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; HEPG2 CELL LINE; HUMAN; IMMUNOLOGY; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; SURVIVAL; TRANSPLANTATION; TUMOR VOLUME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HEP G2 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900460098     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.03.007     Document Type: Article

References (31)

1. Bertelli R., Neri F., Tsivian M., Ruhrman N., Cavallari G., Beltempo P., Puviani L., DeVinci C., Pizza G., Nardo B. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant. Proc. 2008, 40:1913-1915.
2. Biglari A., Southgate T.D., Fairbairn L.J., Gilham D.E. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumor cells in vitro and in vivo. Gene Ther. 2006, 13:602-610.
3. Cerwenka A., Lanier L.L. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 2001, 1:41-49.
4. Di Carlo E., Meazza R., Basso S., Rosso O., Comes A., Gaggero A., Musiani P., Santi L., Ferrini S. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice. J. Pathol. 2000, 191:193-201.
5. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 2001, 97:14-32.
6. Greten T.F., Manns M.P., Korangy F. Immunotherapy of HCC. Rev. Recent Clin. Trials 2008, 3:31-39.
7. Grund E.M., Spyropoulos D.D., Watson D.K., Muise-Helmericks R.C. Interleukins 2 and 15 regulate Ets1 expression via ERK1/2 and MNK1 in human natural killer cells. J. Biol. Chem. 2004, 280:4772-4778.
8. He Y.G., Mayhew E., Mellon J., Niederkorn J.Y. Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:4240-4246.
9. Iwashita Y., Goto S., Tahara K., Kawano K., Chen C.L., Kitano S. Potent stimuli combined with lipopolysaccaride and IFNgamma may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells. Cancer Biother. Radiopharm. 2003, 18:1-6.
10. Jiang W., Zhang J., Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy 2008, 10:265-274.
11. Kärre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
12. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R., Brasel K., Morrissey P.J., Stocking K., Schuh J.C., Joyce S., Peschon J.J. Reversible defects in natural killer and memory CD8T cell lineages in IL-15 deficient mice. J. Exp. Med. 2000, 191:771-780.
13. Kershaw M.H., Teng M.W., Smyth M.J., Darcy P.K. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 2005, 5:928-940.
14. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 2007, 7:329-339.
15. Lodolce J.P., Boone D.L., Chai S., Swain R.E., Dassopoulos T., Trettin S., Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
16. Maasho K., Marusina A., Reynolds N.M., Coligan J.E., Borrego F. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system™. J. Immunol. Methods 2004, 284:133-140.
17. Miller J. The biology of natural killer cells in cancer, infection, and pregnancy. Exp. Hematol. 2001, 29:1157-1168.
18. Nagashima S., Mailliard R., Kashii Y., Reichert T.E., Herberman R.B., Robbins P., Whiteside T.L. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998, 91:3850-3861.
19. Robertson M.J., Cochran K.J., Cameron C., Le J.M., Tantravahi R., Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996, 24:406-415.
20. Roder J.C., Pross H.F. The biology of the human natural killer cell. J. Clin. Immunol. 1982, 24:249-263.
21. Smyth M.J., Kelly J.M., Baxter A.G., Körner H., Sedgwick J.D. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med. 1998, 188:1611-1619.
22. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Yagita H., Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 2001, 193:661-670.
23. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin. Cancer Biol. 2006, 16:412-418.
24. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 2009, 266:154-181.
25. Suzuki K., Nakazato H., Matsui H., Hasumi M., Shibata Y., Ito K., Fukabori Y., Kurokawa K., Yamanaka H. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J. Leukoc. Biol. 2001, 69:531-537.
26. Tonn T., Becker S., Esser R., Schwabe D., Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J. Hematother. Stem Cell Res. 2001, 10:535-544.
27. van den Broek M.F., Kägi D., Zinkernagel R.M., Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 1995, 25:3514-3516.
28. Xu Y., Darcy P.K., Kershaw M.H. Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, ErbB2. Cancer Gene Ther. 2007, 14:773-780.
29. Zhang J., Sun R., Wei H., Zhang J., Tian Z. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy. Oncol. Rep. 2004, 11:1097-1106.
30. Zhang J., Sun R., Wei H., Zhang J.H., Tian Z.G. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 2004, 89:338-347.
31. Zou Y., Chen T., Han M., Wang H., Yan W., Song G., Wu Z., Wang X., Zhu C., Luo X., Ning Q. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J. Immunol. 2010, 184:466-475.